| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| High-Throughput Nucleotide Sequencing | 55 | 2023 | 2335 | 5.090 |
Why?
|
| DNA Mutational Analysis | 57 | 2022 | 2350 | 3.680 |
Why?
|
| Mutation | 129 | 2023 | 15841 | 3.410 |
Why?
|
| Translocation, Genetic | 30 | 2021 | 1287 | 3.020 |
Why?
|
| Polymerase Chain Reaction | 42 | 2019 | 3492 | 2.580 |
Why?
|
| Cell-Free Nucleic Acids | 7 | 2023 | 232 | 2.170 |
Why?
|
| Chromosomes, Human, Pair 14 | 17 | 2013 | 287 | 1.710 |
Why?
|
| Biomarkers, Tumor | 51 | 2023 | 10698 | 1.700 |
Why?
|
| DNA, Neoplasm | 27 | 2018 | 1961 | 1.630 |
Why?
|
| Isocitrate Dehydrogenase | 8 | 2018 | 520 | 1.360 |
Why?
|
| Leukemia, Myeloid, Acute | 34 | 2021 | 7240 | 1.350 |
Why?
|
| Sequence Analysis, DNA | 16 | 2020 | 2560 | 1.340 |
Why?
|
| Myeloproliferative Disorders | 15 | 2022 | 881 | 1.330 |
Why?
|
| Neoplasms | 38 | 2023 | 15849 | 1.320 |
Why?
|
| Proto-Oncogene Proteins B-raf | 19 | 2019 | 1331 | 1.280 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 19 | 2022 | 2474 | 1.190 |
Why?
|
| Chromosomes, Human, Pair 18 | 7 | 2013 | 185 | 1.180 |
Why?
|
| Colorectal Neoplasms | 14 | 2023 | 3657 | 1.140 |
Why?
|
| Fusion Proteins, bcr-abl | 17 | 2019 | 1144 | 1.040 |
Why?
|
| Proto-Oncogene Proteins | 26 | 2023 | 2618 | 1.040 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 19 | 2018 | 841 | 1.000 |
Why?
|
| Microsatellite Instability | 11 | 2017 | 409 | 0.990 |
Why?
|
| Oncogene Proteins, Fusion | 11 | 2021 | 802 | 0.980 |
Why?
|
| Carcinosarcoma | 3 | 2015 | 148 | 0.980 |
Why?
|
| Humans | 287 | 2024 | 270856 | 0.940 |
Why?
|
| Phosphatidylinositol 3-Kinases | 15 | 2019 | 1725 | 0.930 |
Why?
|
| Mutation Rate | 5 | 2019 | 218 | 0.910 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 13 | 2014 | 458 | 0.910 |
Why?
|
| Core Binding Factor beta Subunit | 2 | 2021 | 50 | 0.900 |
Why?
|
| Middle Aged | 169 | 2023 | 90016 | 0.890 |
Why?
|
| Aged, 80 and over | 100 | 2022 | 30941 | 0.880 |
Why?
|
| Aged | 150 | 2023 | 73160 | 0.860 |
Why?
|
| DNA Copy Number Variations | 6 | 2021 | 1543 | 0.840 |
Why?
|
| Lymphoma, Follicular | 6 | 2013 | 636 | 0.840 |
Why?
|
| Nuclear Proteins | 25 | 2016 | 3459 | 0.820 |
Why?
|
| In Situ Hybridization, Fluorescence | 20 | 2023 | 2314 | 0.820 |
Why?
|
| Gene Expression Regulation, Neoplastic | 23 | 2023 | 9078 | 0.820 |
Why?
|
| Philadelphia Chromosome | 9 | 2021 | 834 | 0.820 |
Why?
|
| Myelodysplastic Syndromes | 15 | 2022 | 3145 | 0.810 |
Why?
|
| Electrophoresis, Capillary | 5 | 2011 | 34 | 0.810 |
Why?
|
| Endometrial Neoplasms | 14 | 2018 | 1380 | 0.810 |
Why?
|
| Adult | 155 | 2022 | 81545 | 0.810 |
Why?
|
| Real-Time Polymerase Chain Reaction | 11 | 2017 | 1212 | 0.800 |
Why?
|
| Hematologic Neoplasms | 7 | 2021 | 1955 | 0.800 |
Why?
|
| Chromosomes, Human, Pair 2 | 7 | 2013 | 183 | 0.790 |
Why?
|
| Reproducibility of Results | 27 | 2021 | 6170 | 0.790 |
Why?
|
| Gene Expression Profiling | 16 | 2021 | 5161 | 0.780 |
Why?
|
| Genetic Testing | 8 | 2019 | 1668 | 0.780 |
Why?
|
| Adenocarcinoma | 17 | 2023 | 7936 | 0.770 |
Why?
|
| Biopsy, Fine-Needle | 5 | 2020 | 698 | 0.770 |
Why?
|
| Female | 185 | 2023 | 148467 | 0.760 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2016 | 335 | 0.750 |
Why?
|
| Male | 177 | 2023 | 128412 | 0.750 |
Why?
|
| Genotype | 13 | 2019 | 4109 | 0.750 |
Why?
|
| Myosin Heavy Chains | 1 | 2021 | 124 | 0.740 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 19 | 2015 | 3653 | 0.740 |
Why?
|
| Sensitivity and Specificity | 22 | 2019 | 5185 | 0.740 |
Why?
|
| Carcinoma, Endometrioid | 8 | 2018 | 329 | 0.740 |
Why?
|
| Bone Marrow | 22 | 2021 | 2434 | 0.730 |
Why?
|
| Gene Amplification | 6 | 2017 | 769 | 0.730 |
Why?
|
| Immunohistochemistry | 31 | 2023 | 7809 | 0.720 |
Why?
|
| Esophageal Neoplasms | 12 | 2023 | 3236 | 0.720 |
Why?
|
| ras Proteins | 10 | 2014 | 803 | 0.690 |
Why?
|
| Circulating Tumor DNA | 5 | 2023 | 271 | 0.680 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 15 | 2019 | 2633 | 0.670 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 16 | 2022 | 1408 | 0.670 |
Why?
|
| DNA Barcoding, Taxonomic | 1 | 2019 | 23 | 0.660 |
Why?
|
| Protein Kinase Inhibitors | 18 | 2023 | 4956 | 0.660 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2017 | 189 | 0.650 |
Why?
|
| RNA, Messenger | 12 | 2016 | 6483 | 0.650 |
Why?
|
| Tumor Suppressor Protein p53 | 16 | 2021 | 3657 | 0.650 |
Why?
|
| Specimen Handling | 2 | 2018 | 311 | 0.640 |
Why?
|
| Immunoglobulin Heavy Chains | 9 | 2017 | 248 | 0.640 |
Why?
|
| Genome, Human | 5 | 2021 | 1834 | 0.630 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 6 | 2013 | 1547 | 0.630 |
Why?
|
| Protein-Tyrosine Kinases | 12 | 2023 | 1836 | 0.600 |
Why?
|
| Taq Polymerase | 4 | 2006 | 18 | 0.590 |
Why?
|
| Splenic Neoplasms | 4 | 2016 | 125 | 0.590 |
Why?
|
| Cyclin D1 | 8 | 2013 | 589 | 0.590 |
Why?
|
| Young Adult | 57 | 2021 | 22054 | 0.580 |
Why?
|
| PTEN Phosphohydrolase | 6 | 2017 | 1014 | 0.570 |
Why?
|
| Primary Myelofibrosis | 8 | 2022 | 902 | 0.570 |
Why?
|
| Genes, erbB-1 | 3 | 2016 | 103 | 0.570 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 4 | 2014 | 388 | 0.570 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 11 | 2017 | 2490 | 0.570 |
Why?
|
| Neoplasm Proteins | 15 | 2022 | 3349 | 0.570 |
Why?
|
| Skin Neoplasms | 11 | 2018 | 4836 | 0.560 |
Why?
|
| Microsatellite Repeats | 12 | 2013 | 613 | 0.560 |
Why?
|
| Oncogene Fusion | 1 | 2016 | 62 | 0.560 |
Why?
|
| Chromosome Aberrations | 11 | 2022 | 2023 | 0.540 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 3 | 2014 | 318 | 0.530 |
Why?
|
| Validation Studies as Topic | 1 | 2016 | 42 | 0.530 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2021 | 2899 | 0.530 |
Why?
|
| Lymphoma, Non-Hodgkin | 9 | 2013 | 1068 | 0.530 |
Why?
|
| Genomics | 7 | 2021 | 2817 | 0.520 |
Why?
|
| Computational Biology | 3 | 2019 | 1263 | 0.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 28 | 2024 | 16593 | 0.510 |
Why?
|
| Comparative Genomic Hybridization | 4 | 2014 | 692 | 0.510 |
Why?
|
| Melanoma | 8 | 2018 | 5523 | 0.510 |
Why?
|
| Breast Neoplasms, Male | 1 | 2017 | 231 | 0.510 |
Why?
|
| Prognosis | 56 | 2023 | 22456 | 0.500 |
Why?
|
| MutS Homolog 2 Protein | 12 | 2014 | 172 | 0.500 |
Why?
|
| Antineoplastic Agents | 27 | 2021 | 14678 | 0.490 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 4 | 2020 | 529 | 0.480 |
Why?
|
| Oncogene Proteins | 3 | 2011 | 371 | 0.450 |
Why?
|
| Lymphoma, T-Cell | 5 | 2016 | 369 | 0.450 |
Why?
|
| Bone Marrow Cells | 7 | 2018 | 985 | 0.440 |
Why?
|
| Lymphoma, Mantle-Cell | 6 | 2019 | 746 | 0.420 |
Why?
|
| Neoplasm Metastasis | 7 | 2019 | 5324 | 0.420 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 14 | 2017 | 530 | 0.420 |
Why?
|
| Point Mutation | 6 | 2013 | 791 | 0.410 |
Why?
|
| Poly A | 1 | 2012 | 96 | 0.410 |
Why?
|
| RNA, Neoplasm | 5 | 2021 | 811 | 0.400 |
Why?
|
| Liquid Biopsy | 4 | 2023 | 162 | 0.400 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2016 | 4327 | 0.400 |
Why?
|
| Blast Crisis | 4 | 2013 | 587 | 0.400 |
Why?
|
| Gene Fusion | 3 | 2023 | 213 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 11 | 5 | 2013 | 410 | 0.390 |
Why?
|
| MicroRNAs | 6 | 2014 | 2906 | 0.380 |
Why?
|
| Receptor, ErbB-2 | 3 | 2019 | 2648 | 0.380 |
Why?
|
| Adolescent | 53 | 2021 | 32556 | 0.370 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 337 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 5 | 6 | 2014 | 254 | 0.360 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2011 | 188 | 0.360 |
Why?
|
| Pyrimidines | 17 | 2018 | 3666 | 0.360 |
Why?
|
| Cytodiagnosis | 3 | 2020 | 227 | 0.350 |
Why?
|
| Transition Temperature | 1 | 2009 | 7 | 0.350 |
Why?
|
| Janus Kinase 2 | 9 | 2022 | 753 | 0.350 |
Why?
|
| Oncogenes | 1 | 2013 | 700 | 0.350 |
Why?
|
| Workflow | 5 | 2019 | 291 | 0.350 |
Why?
|
| GTP Phosphohydrolases | 5 | 2019 | 340 | 0.340 |
Why?
|
| Tandem Repeat Sequences | 5 | 2013 | 202 | 0.340 |
Why?
|
| DNA-Binding Proteins | 15 | 2015 | 5042 | 0.340 |
Why?
|
| Ovarian Neoplasms | 8 | 2014 | 4774 | 0.330 |
Why?
|
| Base Sequence | 12 | 2012 | 5495 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 7 | 3 | 2016 | 228 | 0.330 |
Why?
|
| Adaptor Proteins, Signal Transducing | 12 | 2014 | 1467 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2009 | 347 | 0.330 |
Why?
|
| Immunoglobulin Variable Region | 4 | 2017 | 176 | 0.330 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 4 | 2020 | 215 | 0.330 |
Why?
|
| Gene Rearrangement | 5 | 2023 | 817 | 0.320 |
Why?
|
| Germ-Line Mutation | 8 | 2019 | 1069 | 0.320 |
Why?
|
| DNA Mismatch Repair | 4 | 2016 | 276 | 0.320 |
Why?
|
| Annexin A1 | 1 | 2008 | 41 | 0.310 |
Why?
|
| Calreticulin | 4 | 2016 | 87 | 0.310 |
Why?
|
| Cell Line, Tumor | 13 | 2019 | 14864 | 0.310 |
Why?
|
| Leukemia, Hairy Cell | 3 | 2016 | 129 | 0.310 |
Why?
|
| Kaplan-Meier Estimate | 18 | 2019 | 6248 | 0.310 |
Why?
|
| Multigene Family | 2 | 2007 | 459 | 0.310 |
Why?
|
| Lymphoma, B-Cell | 7 | 2015 | 935 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-akt | 10 | 2019 | 2093 | 0.300 |
Why?
|
| Neoplasms, Second Primary | 5 | 2019 | 1379 | 0.300 |
Why?
|
| DNA Primers | 9 | 2011 | 1508 | 0.300 |
Why?
|
| Lymphatic Diseases | 1 | 2008 | 130 | 0.290 |
Why?
|
| Lung Neoplasms | 9 | 2024 | 11761 | 0.290 |
Why?
|
| Retrospective Studies | 38 | 2023 | 39688 | 0.280 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2008 | 331 | 0.280 |
Why?
|
| Dasatinib | 8 | 2020 | 881 | 0.280 |
Why?
|
| Thiazoles | 7 | 2015 | 729 | 0.280 |
Why?
|
| Leukemia, Myeloid | 4 | 2017 | 994 | 0.270 |
Why?
|
| Biopsy, Large-Core Needle | 2 | 2017 | 139 | 0.270 |
Why?
|
| Down-Regulation | 3 | 2015 | 2109 | 0.270 |
Why?
|
| Barrett Esophagus | 2 | 2009 | 561 | 0.270 |
Why?
|
| Gene Regulatory Networks | 1 | 2010 | 671 | 0.270 |
Why?
|
| Precision Medicine | 5 | 2020 | 1201 | 0.270 |
Why?
|
| Disease-Free Survival | 21 | 2022 | 10249 | 0.270 |
Why?
|
| MutL Protein Homolog 1 | 12 | 2014 | 197 | 0.270 |
Why?
|
| Exons | 6 | 2022 | 1379 | 0.260 |
Why?
|
| Treatment Outcome | 39 | 2022 | 33819 | 0.260 |
Why?
|
| Time Factors | 20 | 2019 | 13110 | 0.260 |
Why?
|
| Esophagus | 1 | 2009 | 563 | 0.260 |
Why?
|
| TOR Serine-Threonine Kinases | 7 | 2014 | 1571 | 0.250 |
Why?
|
| Anemia, Sideroblastic | 2 | 2019 | 58 | 0.250 |
Why?
|
| Survival Rate | 22 | 2023 | 12516 | 0.250 |
Why?
|
| Immunophenotyping | 15 | 2018 | 1730 | 0.250 |
Why?
|
| World Health Organization | 5 | 2020 | 329 | 0.250 |
Why?
|
| Thyroid Neoplasms | 5 | 2019 | 1894 | 0.250 |
Why?
|
| Follow-Up Studies | 24 | 2020 | 15247 | 0.250 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2024 | 5517 | 0.250 |
Why?
|
| Neoplasm, Residual | 7 | 2020 | 1740 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 17 | 3 | 2017 | 663 | 0.240 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 2 | 2017 | 120 | 0.240 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 9 | 2014 | 685 | 0.240 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 4 | 2016 | 172 | 0.240 |
Why?
|
| Loss of Heterozygosity | 3 | 2016 | 624 | 0.240 |
Why?
|
| Genes, ras | 5 | 2012 | 680 | 0.240 |
Why?
|
| Cohort Studies | 11 | 2019 | 9430 | 0.240 |
Why?
|
| Survival Analysis | 15 | 2020 | 9305 | 0.240 |
Why?
|
| In Situ Hybridization | 3 | 2019 | 1062 | 0.230 |
Why?
|
| Genes, bcl-2 | 1 | 2004 | 175 | 0.230 |
Why?
|
| Piperazines | 10 | 2013 | 2153 | 0.230 |
Why?
|
| Genes, p53 | 4 | 2017 | 1133 | 0.230 |
Why?
|
| Genetic Techniques | 1 | 2004 | 150 | 0.230 |
Why?
|
| CD13 Antigens | 1 | 2023 | 43 | 0.220 |
Why?
|
| Receptor, Notch1 | 2 | 2022 | 220 | 0.220 |
Why?
|
| Sequence Analysis, RNA | 3 | 2023 | 675 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 19 | 3 | 2013 | 153 | 0.220 |
Why?
|
| Bone Marrow Neoplasms | 2 | 2015 | 128 | 0.220 |
Why?
|
| Carrier Proteins | 9 | 2016 | 2123 | 0.220 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2024 | 5567 | 0.220 |
Why?
|
| Disease Progression | 16 | 2018 | 6890 | 0.220 |
Why?
|
| Gene Dosage | 3 | 2017 | 827 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 5 | 2023 | 4067 | 0.210 |
Why?
|
| RNA, Bacterial | 1 | 2002 | 84 | 0.210 |
Why?
|
| Cladribine | 2 | 2016 | 253 | 0.210 |
Why?
|
| Leukemia | 2 | 2018 | 1720 | 0.210 |
Why?
|
| Lymphoma | 2 | 2017 | 1514 | 0.210 |
Why?
|
| Abnormal Karyotype | 3 | 2018 | 101 | 0.210 |
Why?
|
| Pyrazoles | 5 | 2018 | 1542 | 0.210 |
Why?
|
| Neoplasms, Multiple Primary | 4 | 2014 | 559 | 0.210 |
Why?
|
| Mycobacterium | 1 | 2002 | 60 | 0.210 |
Why?
|
| Bacterial Typing Techniques | 1 | 2002 | 142 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 8 | 4 | 2016 | 327 | 0.210 |
Why?
|
| Predictive Value of Tests | 7 | 2021 | 4983 | 0.200 |
Why?
|
| Karyotyping | 10 | 2017 | 1064 | 0.200 |
Why?
|
| Cytarabine | 9 | 2016 | 2014 | 0.200 |
Why?
|
| Breast Neoplasms | 5 | 2019 | 16186 | 0.200 |
Why?
|
| Antigens, CD20 | 1 | 2002 | 210 | 0.200 |
Why?
|
| Exonucleases | 2 | 2000 | 51 | 0.200 |
Why?
|
| Cytogenetic Analysis | 3 | 2013 | 574 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 10349 | 0.200 |
Why?
|
| Imatinib Mesylate | 11 | 2020 | 1691 | 0.200 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2002 | 382 | 0.200 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 2021 | 54 | 0.200 |
Why?
|
| Genes, Bacterial | 1 | 2002 | 271 | 0.200 |
Why?
|
| Centrifugation | 2 | 2019 | 65 | 0.200 |
Why?
|
| Gene Frequency | 3 | 2019 | 1187 | 0.200 |
Why?
|
| Remission Induction | 13 | 2018 | 3645 | 0.200 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2021 | 48 | 0.190 |
Why?
|
| Biological Assay | 2 | 2021 | 182 | 0.190 |
Why?
|
| Sequence Deletion | 3 | 2013 | 909 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2022 | 5411 | 0.190 |
Why?
|
| Gene Library | 2 | 2019 | 357 | 0.190 |
Why?
|
| Microdissection | 2 | 2012 | 86 | 0.190 |
Why?
|
| Hedgehog Proteins | 3 | 2009 | 441 | 0.190 |
Why?
|
| Membrane Proteins | 5 | 2019 | 2952 | 0.190 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2022 | 178 | 0.190 |
Why?
|
| Nucleic Acid Denaturation | 2 | 2011 | 50 | 0.190 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2016 | 582 | 0.190 |
Why?
|
| Serine-Arginine Splicing Factors | 2 | 2022 | 84 | 0.180 |
Why?
|
| Support Vector Machine | 1 | 2020 | 42 | 0.180 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2017 | 504 | 0.180 |
Why?
|
| Chromosome Inversion | 1 | 2021 | 189 | 0.180 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2002 | 508 | 0.180 |
Why?
|
| Cytological Techniques | 1 | 2020 | 75 | 0.180 |
Why?
|
| Benzamides | 11 | 2018 | 1883 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 12 | 2019 | 5435 | 0.180 |
Why?
|
| Algorithms | 1 | 2011 | 3908 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 6 | 2018 | 2399 | 0.170 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 2 | 2010 | 37 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2021 | 254 | 0.170 |
Why?
|
| Clonal Evolution | 3 | 2017 | 251 | 0.170 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2014 | 461 | 0.170 |
Why?
|
| Thrombocytosis | 2 | 2011 | 141 | 0.170 |
Why?
|
| Polycythemia Vera | 3 | 2013 | 267 | 0.170 |
Why?
|
| Exodeoxyribonucleases | 1 | 1999 | 108 | 0.170 |
Why?
|
| Alleles | 7 | 2017 | 2507 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2018 | 2471 | 0.170 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2019 | 59 | 0.160 |
Why?
|
| Limit of Detection | 1 | 2019 | 84 | 0.160 |
Why?
|
| X-linked Nuclear Protein | 1 | 2019 | 55 | 0.160 |
Why?
|
| Biopsy | 9 | 2021 | 3544 | 0.160 |
Why?
|
| Vincristine | 7 | 2019 | 1572 | 0.160 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2018 | 162 | 0.160 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2016 | 439 | 0.160 |
Why?
|
| Subarachnoid Space | 1 | 2018 | 38 | 0.160 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2001 | 185 | 0.160 |
Why?
|
| Eosinophilia | 1 | 2020 | 189 | 0.160 |
Why?
|
| Hypereosinophilic Syndrome | 2 | 2009 | 86 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 21 | 2 | 2009 | 102 | 0.150 |
Why?
|
| Trisomy | 3 | 2016 | 239 | 0.150 |
Why?
|
| Antigens, CD | 8 | 2013 | 1435 | 0.150 |
Why?
|
| Dexamethasone | 7 | 2019 | 1506 | 0.150 |
Why?
|
| Thyroid Nodule | 1 | 2019 | 94 | 0.150 |
Why?
|
| Paraffin Embedding | 4 | 2018 | 226 | 0.150 |
Why?
|
| Molecular Sequence Data | 7 | 2012 | 6784 | 0.150 |
Why?
|
| Immunoglobulin Joining Region | 3 | 2002 | 16 | 0.150 |
Why?
|
| Mutation, Missense | 5 | 2017 | 1181 | 0.150 |
Why?
|
| Combined Modality Therapy | 9 | 2017 | 9042 | 0.150 |
Why?
|
| Cyclophosphamide | 8 | 2019 | 3231 | 0.150 |
Why?
|
| Mastocytosis, Systemic | 2 | 2009 | 119 | 0.150 |
Why?
|
| Keratin-7 | 2 | 2016 | 50 | 0.150 |
Why?
|
| Cluster Analysis | 3 | 2010 | 1070 | 0.150 |
Why?
|
| Transcriptome | 3 | 2021 | 1934 | 0.150 |
Why?
|
| Chromothripsis | 1 | 2017 | 12 | 0.150 |
Why?
|
| Antibodies, Bispecific | 1 | 2021 | 274 | 0.150 |
Why?
|
| Clinical Laboratory Services | 1 | 2017 | 38 | 0.140 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2019 | 262 | 0.140 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 2 | 2017 | 121 | 0.140 |
Why?
|
| Chromosome Mapping | 2 | 2022 | 1585 | 0.140 |
Why?
|
| Blood Platelet Disorders | 1 | 2017 | 35 | 0.140 |
Why?
|
| Leukemia, Lymphoid | 1 | 2017 | 291 | 0.140 |
Why?
|
| Molecular Probes | 1 | 2017 | 71 | 0.140 |
Why?
|
| Radiotherapy | 5 | 2015 | 1858 | 0.140 |
Why?
|
| Neurilemmoma | 1 | 2018 | 134 | 0.140 |
Why?
|
| Genes, Neoplasm | 3 | 2014 | 315 | 0.140 |
Why?
|
| NF-kappa B | 4 | 2007 | 1583 | 0.140 |
Why?
|
| Phenotype | 10 | 2018 | 6464 | 0.140 |
Why?
|
| Pathology Department, Hospital | 1 | 2016 | 16 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2019 | 428 | 0.140 |
Why?
|
| Thyroid Gland | 1 | 2019 | 370 | 0.140 |
Why?
|
| Artifacts | 1 | 2019 | 537 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2017 | 155 | 0.140 |
Why?
|
| Rituximab | 3 | 2017 | 1589 | 0.140 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 319 | 0.130 |
Why?
|
| Cyclins | 3 | 2006 | 470 | 0.130 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 3 | 2011 | 103 | 0.130 |
Why?
|
| Genome-Wide Association Study | 2 | 2017 | 2083 | 0.130 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2016 | 66 | 0.130 |
Why?
|
| Neoplasm Staging | 14 | 2018 | 13976 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 7 | 2013 | 5834 | 0.130 |
Why?
|
| Microarray Analysis | 1 | 2017 | 396 | 0.130 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2015 | 23 | 0.130 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2018 | 230 | 0.130 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2016 | 99 | 0.130 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 550 | 0.130 |
Why?
|
| Flow Cytometry | 10 | 2013 | 3083 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 2366 | 0.130 |
Why?
|
| Proportional Hazards Models | 9 | 2017 | 5086 | 0.130 |
Why?
|
| Genes, erbB-2 | 1 | 2016 | 228 | 0.130 |
Why?
|
| Transplant Recipients | 1 | 2018 | 337 | 0.130 |
Why?
|
| Thrombocythemia, Essential | 3 | 2016 | 179 | 0.130 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2007 | 222 | 0.130 |
Why?
|
| Karyopherins | 1 | 2016 | 134 | 0.130 |
Why?
|
| Carcinoma, Lobular | 1 | 2019 | 617 | 0.130 |
Why?
|
| Inclusion Bodies | 1 | 2015 | 91 | 0.130 |
Why?
|
| Megakaryocytes | 1 | 2016 | 131 | 0.130 |
Why?
|
| Liver Neoplasms | 4 | 2016 | 4787 | 0.130 |
Why?
|
| Histiocytosis | 1 | 2015 | 56 | 0.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 8 | 2018 | 1734 | 0.120 |
Why?
|
| ErbB Receptors | 5 | 2023 | 2379 | 0.120 |
Why?
|
| Antibodies | 1 | 2018 | 835 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2017 | 377 | 0.120 |
Why?
|
| Brain Neoplasms | 3 | 2019 | 4983 | 0.120 |
Why?
|
| Bone Marrow Examination | 3 | 2016 | 151 | 0.120 |
Why?
|
| False Negative Reactions | 1 | 2015 | 293 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 6 | 2014 | 1214 | 0.120 |
Why?
|
| Standard of Care | 1 | 2016 | 274 | 0.120 |
Why?
|
| Karyotype | 4 | 2017 | 237 | 0.120 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 278 | 0.120 |
Why?
|
| DNA Repair Enzymes | 2 | 2014 | 234 | 0.120 |
Why?
|
| Genes, abl | 2 | 2012 | 120 | 0.120 |
Why?
|
| Doxorubicin | 7 | 2019 | 3138 | 0.120 |
Why?
|
| Thrombocytopenia | 2 | 2017 | 871 | 0.110 |
Why?
|
| Fluorescent Dyes | 3 | 2004 | 467 | 0.110 |
Why?
|
| Meningeal Neoplasms | 1 | 2018 | 473 | 0.110 |
Why?
|
| Eye Neoplasms | 1 | 2016 | 259 | 0.110 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2016 | 273 | 0.110 |
Why?
|
| Core Binding Factors | 1 | 2014 | 113 | 0.110 |
Why?
|
| Smad4 Protein | 1 | 2015 | 200 | 0.110 |
Why?
|
| Receptors, Erythropoietin | 1 | 2013 | 76 | 0.110 |
Why?
|
| Ribonucleotide Reductases | 1 | 2013 | 48 | 0.110 |
Why?
|
| Mitochondria, Liver | 3 | 1978 | 54 | 0.110 |
Why?
|
| Neutropenia | 2 | 2015 | 1001 | 0.110 |
Why?
|
| Muir-Torre Syndrome | 1 | 2013 | 18 | 0.110 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 2013 | 114 | 0.110 |
Why?
|
| Child | 18 | 2021 | 30380 | 0.110 |
Why?
|
| Mycosis Fungoides | 3 | 2018 | 335 | 0.110 |
Why?
|
| Risk Assessment | 8 | 2020 | 6832 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 3 | 2013 | 1469 | 0.110 |
Why?
|
| Repressor Proteins | 3 | 2016 | 1726 | 0.110 |
Why?
|
| Interferon-alpha | 2 | 2009 | 960 | 0.110 |
Why?
|
| Genetic Variation | 3 | 2019 | 2087 | 0.100 |
Why?
|
| Mutant Proteins | 1 | 2013 | 235 | 0.100 |
Why?
|
| Breast | 1 | 2019 | 1364 | 0.100 |
Why?
|
| Genomic Instability | 2 | 2007 | 522 | 0.100 |
Why?
|
| Chromosome Disorders | 1 | 2015 | 425 | 0.100 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2016 | 284 | 0.100 |
Why?
|
| Mutagenesis, Insertional | 1 | 2013 | 218 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2018 | 7294 | 0.100 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2015 | 381 | 0.100 |
Why?
|
| Erythroid Precursor Cells | 1 | 2012 | 70 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2019 | 1233 | 0.100 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2016 | 286 | 0.100 |
Why?
|
| Nitriles | 4 | 2018 | 943 | 0.100 |
Why?
|
| Body Mass Index | 2 | 2018 | 2237 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2014 | 191 | 0.100 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2012 | 38 | 0.100 |
Why?
|
| Chromosomal Instability | 1 | 2013 | 229 | 0.100 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 641 | 0.100 |
Why?
|
| HL-60 Cells | 2 | 2002 | 318 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2012 | 100 | 0.100 |
Why?
|
| WT1 Proteins | 1 | 2012 | 107 | 0.100 |
Why?
|
| Adenosine Triphosphatases | 3 | 2014 | 428 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 429 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2010 | 291 | 0.100 |
Why?
|
| DNA | 2 | 2013 | 3072 | 0.090 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2011 | 85 | 0.090 |
Why?
|
| Anemia, Refractory | 1 | 2011 | 40 | 0.090 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2017 | 741 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 1424 | 0.090 |
Why?
|
| Immunosuppressive Agents | 2 | 2011 | 1443 | 0.090 |
Why?
|
| Complementarity Determining Regions | 1 | 2010 | 44 | 0.090 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2013 | 401 | 0.090 |
Why?
|
| Polymorphism, Genetic | 3 | 2009 | 1522 | 0.090 |
Why?
|
| Carcinoma | 3 | 2006 | 2627 | 0.090 |
Why?
|
| Ikaros Transcription Factor | 1 | 2010 | 52 | 0.090 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2013 | 299 | 0.090 |
Why?
|
| Metaplasia | 2 | 2009 | 386 | 0.090 |
Why?
|
| DNA Repair | 2 | 2013 | 1886 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 2029 | 0.090 |
Why?
|
| Software | 1 | 2017 | 1361 | 0.090 |
Why?
|
| Classification | 1 | 2009 | 40 | 0.090 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2010 | 71 | 0.090 |
Why?
|
| Age Factors | 6 | 2020 | 5492 | 0.090 |
Why?
|
| Texas | 8 | 2014 | 6413 | 0.090 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 218 | 0.090 |
Why?
|
| Biomarkers | 5 | 2022 | 5105 | 0.090 |
Why?
|
| Clone Cells | 4 | 2010 | 592 | 0.090 |
Why?
|
| Recurrence | 5 | 2018 | 4880 | 0.080 |
Why?
|
| DNA Methylation | 4 | 2014 | 2736 | 0.080 |
Why?
|
| Hodgkin Disease | 5 | 2000 | 1486 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2022 | 2435 | 0.080 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 3 | 2004 | 67 | 0.080 |
Why?
|
| Calgranulin B | 1 | 2009 | 22 | 0.080 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2009 | 27 | 0.080 |
Why?
|
| Idarubicin | 4 | 2014 | 459 | 0.080 |
Why?
|
| Child, Preschool | 9 | 2017 | 16957 | 0.080 |
Why?
|
| Keratin-5 | 1 | 2009 | 57 | 0.080 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2010 | 174 | 0.080 |
Why?
|
| Vidarabine | 3 | 2017 | 1383 | 0.080 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2009 | 123 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 704 | 0.080 |
Why?
|
| Cold Temperature | 1 | 2009 | 129 | 0.080 |
Why?
|
| Cell-Free System | 2 | 2021 | 175 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 1437 | 0.080 |
Why?
|
| Astrocytoma | 1 | 2011 | 335 | 0.080 |
Why?
|
| Drug Administration Schedule | 4 | 2017 | 3540 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 880 | 0.080 |
Why?
|
| Papillomavirus Infections | 2 | 2007 | 1009 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 1004 | 0.080 |
Why?
|
| Signal Transduction | 10 | 2019 | 12205 | 0.080 |
Why?
|
| Genetic Association Studies | 3 | 2020 | 1065 | 0.080 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 624 | 0.080 |
Why?
|
| Gene Duplication | 2 | 2013 | 433 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2012 | 1913 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2010 | 323 | 0.080 |
Why?
|
| Chromosome Deletion | 4 | 2015 | 1056 | 0.080 |
Why?
|
| Chlortetracycline | 2 | 1978 | 2 | 0.080 |
Why?
|
| Biopsy, Needle | 4 | 2017 | 1400 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2008 | 130 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 912 | 0.080 |
Why?
|
| Genetic Markers | 3 | 2016 | 1015 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2008 | 187 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 1 | 2009 | 276 | 0.070 |
Why?
|
| Telomere-Binding Proteins | 1 | 2008 | 85 | 0.070 |
Why?
|
| Microfluidics | 1 | 2007 | 32 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 1323 | 0.070 |
Why?
|
| Amino Acid Substitution | 3 | 2016 | 658 | 0.070 |
Why?
|
| Risk Factors | 8 | 2019 | 17820 | 0.070 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 632 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2013 | 1108 | 0.070 |
Why?
|
| Calcium | 3 | 1978 | 1597 | 0.070 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2006 | 47 | 0.070 |
Why?
|
| Microsomes, Liver | 2 | 2001 | 119 | 0.070 |
Why?
|
| Mast Cells | 1 | 2008 | 231 | 0.070 |
Why?
|
| Spleen | 2 | 2015 | 736 | 0.070 |
Why?
|
| Multivariate Analysis | 5 | 2012 | 4331 | 0.070 |
Why?
|
| Methotrexate | 3 | 2016 | 1027 | 0.070 |
Why?
|
| Adenoma | 1 | 2011 | 741 | 0.070 |
Why?
|
| Genes, myc | 1 | 2008 | 373 | 0.070 |
Why?
|
| Lymphomatoid Papulosis | 2 | 1997 | 68 | 0.070 |
Why?
|
| DNA Sequence, Unstable | 1 | 2006 | 7 | 0.070 |
Why?
|
| Acute Disease | 4 | 2017 | 2515 | 0.070 |
Why?
|
| Frameshift Mutation | 2 | 2004 | 234 | 0.070 |
Why?
|
| Tissue Fixation | 2 | 2017 | 139 | 0.070 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2006 | 38 | 0.070 |
Why?
|
| Azacitidine | 3 | 2018 | 1215 | 0.070 |
Why?
|
| Neoplasm Grading | 3 | 2016 | 1820 | 0.070 |
Why?
|
| Jurkat Cells | 2 | 2009 | 319 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2009 | 641 | 0.060 |
Why?
|
| Leukocyte Count | 3 | 2013 | 738 | 0.060 |
Why?
|
| Laser Capture Microdissection | 2 | 2015 | 45 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2014 | 490 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2010 | 1482 | 0.060 |
Why?
|
| Apoptosis | 2 | 2013 | 7847 | 0.060 |
Why?
|
| Dichloroethylenes | 1 | 1984 | 1 | 0.060 |
Why?
|
| Human papillomavirus 16 | 1 | 2006 | 256 | 0.060 |
Why?
|
| Cyclophilins | 1 | 2004 | 29 | 0.060 |
Why?
|
| Carbon Tetrachloride | 1 | 1984 | 25 | 0.060 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 1984 | 14 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 1424 | 0.060 |
Why?
|
| Telomere | 1 | 2008 | 534 | 0.060 |
Why?
|
| Transcription Factors | 3 | 2015 | 5494 | 0.060 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1984 | 70 | 0.060 |
Why?
|
| Aminoglycosides | 2 | 2016 | 235 | 0.060 |
Why?
|
| Viral Load | 1 | 2006 | 482 | 0.060 |
Why?
|
| Genital Neoplasms, Female | 1 | 2012 | 790 | 0.060 |
Why?
|
| Genes, MHC Class I | 1 | 2004 | 48 | 0.060 |
Why?
|
| Genes, MHC Class II | 1 | 2004 | 68 | 0.060 |
Why?
|
| Intermediate Filament Proteins | 1 | 2004 | 83 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2004 | 196 | 0.060 |
Why?
|
| Papillomaviridae | 1 | 2007 | 642 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2015 | 145 | 0.060 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 580 | 0.060 |
Why?
|
| Infant | 5 | 2019 | 13891 | 0.060 |
Why?
|
| Dioxygenases | 2 | 2015 | 170 | 0.060 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 2 | 2014 | 48 | 0.050 |
Why?
|
| Radiation Tolerance | 1 | 2006 | 635 | 0.050 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2004 | 183 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2014 | 316 | 0.050 |
Why?
|
| Archives | 1 | 2002 | 5 | 0.050 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2002 | 41 | 0.050 |
Why?
|
| Cyclophilin A | 1 | 2002 | 23 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2008 | 1522 | 0.050 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2015 | 2412 | 0.050 |
Why?
|
| DNA, Ribosomal | 1 | 2002 | 105 | 0.050 |
Why?
|
| Rectum | 2 | 2017 | 479 | 0.050 |
Why?
|
| Sarcoma | 1 | 2013 | 1840 | 0.050 |
Why?
|
| Leukocytosis | 2 | 2014 | 115 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2011 | 2359 | 0.050 |
Why?
|
| Chromosome Banding | 1 | 2022 | 280 | 0.050 |
Why?
|
| Carcinoma, Papillary | 1 | 2006 | 581 | 0.050 |
Why?
|
| Digestive System | 1 | 2002 | 121 | 0.050 |
Why?
|
| Ribosomal Proteins | 1 | 2002 | 135 | 0.050 |
Why?
|
| Trichloroethanes | 1 | 2001 | 1 | 0.050 |
Why?
|
| Viral Proteins | 1 | 2004 | 494 | 0.050 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2004 | 244 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2021 | 2287 | 0.050 |
Why?
|
| Sampling Studies | 2 | 2015 | 169 | 0.050 |
Why?
|
| Methylation | 1 | 2023 | 626 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 3142 | 0.050 |
Why?
|
| Species Specificity | 1 | 2002 | 809 | 0.050 |
Why?
|
| Solvents | 1 | 2001 | 68 | 0.050 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2001 | 41 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2006 | 1850 | 0.050 |
Why?
|
| Colon | 2 | 2017 | 689 | 0.050 |
Why?
|
| Drug Evaluation | 2 | 2013 | 435 | 0.050 |
Why?
|
| Receptors, Chemokine | 1 | 2001 | 113 | 0.050 |
Why?
|
| Hepatomegaly | 2 | 2016 | 72 | 0.050 |
Why?
|
| Cell Line | 2 | 2020 | 5435 | 0.050 |
Why?
|
| Adenine | 2 | 2018 | 667 | 0.050 |
Why?
|
| Chromosome Fragility | 1 | 2000 | 33 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2014 | 621 | 0.050 |
Why?
|
| Niacinamide | 2 | 2014 | 428 | 0.050 |
Why?
|
| Lymph Nodes | 4 | 2006 | 3067 | 0.040 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2021 | 224 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2002 | 604 | 0.040 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 1066 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 2984 | 0.040 |
Why?
|
| Exodeoxyribonuclease V | 1 | 1999 | 30 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2020 | 154 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2014 | 1502 | 0.040 |
Why?
|
| Chromosome Breakage | 1 | 2000 | 224 | 0.040 |
Why?
|
| Splenomegaly | 2 | 2016 | 173 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 2009 | 3415 | 0.040 |
Why?
|
| Burkitt Lymphoma | 1 | 2002 | 350 | 0.040 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2021 | 166 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 435 | 0.040 |
Why?
|
| Receptors, Progesterone | 2 | 2016 | 1645 | 0.040 |
Why?
|
| RNA-Binding Proteins | 2 | 2022 | 1019 | 0.040 |
Why?
|
| Time | 1 | 2020 | 185 | 0.040 |
Why?
|
| Appendiceal Neoplasms | 1 | 2002 | 250 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2013 | 6982 | 0.040 |
Why?
|
| Tretinoin | 2 | 2016 | 621 | 0.040 |
Why?
|
| Computer Systems | 1 | 1999 | 117 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2024 | 758 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2015 | 2288 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2019 | 64 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 2 | 2014 | 887 | 0.040 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2002 | 441 | 0.040 |
Why?
|
| Phenylurea Compounds | 2 | 2014 | 601 | 0.040 |
Why?
|
| RNA | 1 | 2023 | 1067 | 0.040 |
Why?
|
| Cell Cycle | 3 | 2013 | 2151 | 0.040 |
Why?
|
| Giant Cells | 1 | 2018 | 73 | 0.040 |
Why?
|
| Clinical Trials as Topic | 3 | 2017 | 3862 | 0.040 |
Why?
|
| Ruthenium Red | 1 | 1977 | 8 | 0.040 |
Why?
|
| Ruthenium | 1 | 1977 | 8 | 0.040 |
Why?
|
| Thinness | 1 | 2018 | 82 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2016 | 3395 | 0.040 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 4890 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2002 | 954 | 0.040 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 2264 | 0.040 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2002 | 475 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 157 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2018 | 356 | 0.040 |
Why?
|
| Osteoclasts | 1 | 2018 | 158 | 0.040 |
Why?
|
| Reference Standards | 1 | 2019 | 368 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2018 | 175 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2018 | 6027 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2002 | 721 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2018 | 194 | 0.040 |
Why?
|
| Quinazolines | 1 | 2022 | 953 | 0.040 |
Why?
|
| Rats | 8 | 2001 | 6635 | 0.040 |
Why?
|
| Arabinonucleosides | 1 | 2019 | 458 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2022 | 1135 | 0.040 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 1325 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2024 | 1887 | 0.040 |
Why?
|
| DNA Probes | 2 | 2011 | 248 | 0.030 |
Why?
|
| Safety | 1 | 2018 | 466 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2018 | 272 | 0.030 |
Why?
|
| Observer Variation | 1 | 2019 | 722 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2012 | 4124 | 0.030 |
Why?
|
| Introns | 1 | 1998 | 459 | 0.030 |
Why?
|
| Prospective Studies | 4 | 2018 | 13350 | 0.030 |
Why?
|
| RNA Splicing Factors | 1 | 2017 | 153 | 0.030 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2016 | 66 | 0.030 |
Why?
|
| Therapeutics | 1 | 2016 | 31 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 615 | 0.030 |
Why?
|
| Animals | 12 | 2016 | 62759 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2019 | 449 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2021 | 1758 | 0.030 |
Why?
|
| Oxides | 1 | 2016 | 212 | 0.030 |
Why?
|
| Isochromosomes | 1 | 2016 | 54 | 0.030 |
Why?
|
| Arsenicals | 1 | 2016 | 204 | 0.030 |
Why?
|
| Prevalence | 2 | 2018 | 3417 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 4509 | 0.030 |
Why?
|
| Tissue Embedding | 1 | 2015 | 29 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 184 | 0.030 |
Why?
|
| Pyrazines | 1 | 2018 | 524 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 536 | 0.030 |
Why?
|
| Quality Control | 1 | 2017 | 466 | 0.030 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 2 | 2010 | 41 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 1999 | 631 | 0.030 |
Why?
|
| Histiocytes | 1 | 2015 | 95 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2015 | 116 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2015 | 78 | 0.030 |
Why?
|
| beta Catenin | 2 | 2011 | 690 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2016 | 153 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2016 | 370 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2007 | 763 | 0.030 |
Why?
|
| Overweight | 1 | 2018 | 484 | 0.030 |
Why?
|
| SMARCB1 Protein | 1 | 2015 | 109 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 1995 | 456 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 124 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 490 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 534 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2015 | 291 | 0.030 |
Why?
|
| Semiconductors | 1 | 2014 | 20 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 485 | 0.030 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2014 | 36 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 1994 | 189 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2017 | 706 | 0.030 |
Why?
|
| Syndrome | 2 | 2010 | 1402 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 235 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2023 | 4967 | 0.030 |
Why?
|
| Furans | 1 | 2014 | 103 | 0.030 |
Why?
|
| Carbazoles | 1 | 2014 | 92 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2017 | 551 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 2191 | 0.030 |
Why?
|
| Benzothiazoles | 1 | 2014 | 101 | 0.030 |
Why?
|
| Rats, Inbred Strains | 4 | 1989 | 483 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 209 | 0.030 |
Why?
|
| Cytogenetics | 1 | 2013 | 152 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 2048 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2013 | 5105 | 0.030 |
Why?
|
| Family | 1 | 2017 | 762 | 0.030 |
Why?
|
| Pedigree | 1 | 2017 | 1981 | 0.030 |
Why?
|
| Piperidines | 1 | 2018 | 1089 | 0.030 |
Why?
|
| Lung | 1 | 2024 | 3267 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 730 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 426 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2013 | 190 | 0.030 |
Why?
|
| Medical Records | 1 | 2014 | 443 | 0.030 |
Why?
|
| Protein Subunits | 1 | 2013 | 282 | 0.030 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family Member 1 | 1 | 2011 | 10 | 0.030 |
Why?
|
| Liver | 2 | 2001 | 3124 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 2848 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 606 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1993 | 186 | 0.020 |
Why?
|
| Genetic Counseling | 1 | 2014 | 405 | 0.020 |
Why?
|
| Antigens, Neoplasm | 2 | 2013 | 1589 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2019 | 965 | 0.020 |
Why?
|
| Anemia | 1 | 2017 | 730 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2017 | 1229 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2003 | 380 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 879 | 0.020 |
Why?
|
| Histocompatibility | 1 | 2011 | 182 | 0.020 |
Why?
|
| Cell Size | 1 | 2011 | 145 | 0.020 |
Why?
|
| Lymphocytosis | 1 | 2011 | 58 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 326 | 0.020 |
Why?
|
| MutL Proteins | 2 | 2001 | 28 | 0.020 |
Why?
|
| Mediastinal Neoplasms | 1 | 1994 | 429 | 0.020 |
Why?
|
| Base Pair Mismatch | 2 | 2001 | 79 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 1093 | 0.020 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2010 | 112 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2024 | 3532 | 0.020 |
Why?
|
| Prednisone | 1 | 2013 | 1039 | 0.020 |
Why?
|
| Thrombopoiesis | 1 | 2010 | 23 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 1885 | 0.020 |
Why?
|
| Propane | 1 | 1989 | 31 | 0.020 |
Why?
|
| Insecticides | 1 | 1989 | 51 | 0.020 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 1 | 2009 | 37 | 0.020 |
Why?
|
| Helicobacter pylori | 1 | 1999 | 1433 | 0.020 |
Why?
|
| Helicobacter Infections | 1 | 1999 | 1350 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2014 | 682 | 0.020 |
Why?
|
| Endocrine System Diseases | 1 | 1989 | 91 | 0.020 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 196 | 0.020 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2009 | 115 | 0.020 |
Why?
|
| Biological Transport | 3 | 1983 | 647 | 0.020 |
Why?
|
| Stem Cell Factor | 1 | 2008 | 88 | 0.020 |
Why?
|
| Lymphoid Progenitor Cells | 1 | 2008 | 9 | 0.020 |
Why?
|
| Tryptases | 1 | 2008 | 48 | 0.020 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2008 | 53 | 0.020 |
Why?
|
| Wnt Signaling Pathway | 1 | 2011 | 443 | 0.020 |
Why?
|
| Sex Chromosomes | 1 | 2008 | 43 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2009 | 208 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 2008 | 208 | 0.020 |
Why?
|
| Models, Biological | 2 | 2011 | 3225 | 0.020 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2010 | 205 | 0.020 |
Why?
|
| Salvage Therapy | 2 | 2013 | 2117 | 0.020 |
Why?
|
| Skin | 2 | 2004 | 1280 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1989 | 204 | 0.020 |
Why?
|
| Organ Size | 3 | 2001 | 723 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 908 | 0.020 |
Why?
|
| Eosinophils | 1 | 2009 | 168 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2006 | 3648 | 0.020 |
Why?
|
| T-Lymphocytes | 2 | 2001 | 3928 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 1432 | 0.020 |
Why?
|
| Antimycin A | 2 | 1977 | 13 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2018 | 4190 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 2 | 1978 | 207 | 0.020 |
Why?
|
| VDJ Exons | 1 | 2006 | 7 | 0.020 |
Why?
|
| Cyclin D | 1 | 2006 | 40 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2008 | 377 | 0.020 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 462 | 0.020 |
Why?
|
| Virus Integration | 1 | 2006 | 73 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 1999 | 2317 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1999 | 3172 | 0.020 |
Why?
|
| Guanine | 1 | 2007 | 157 | 0.020 |
Why?
|
| Carbon Tetrachloride Poisoning | 1 | 1986 | 13 | 0.020 |
Why?
|
| Mice, Nude | 2 | 2006 | 4360 | 0.020 |
Why?
|
| Phosphates | 2 | 1977 | 193 | 0.020 |
Why?
|
| Gastric Mucosa | 1 | 2010 | 659 | 0.020 |
Why?
|
| Ornithine Carbamoyltransferase | 2 | 2001 | 22 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2006 | 112 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2007 | 315 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2007 | 251 | 0.020 |
Why?
|
| Obesity | 1 | 2018 | 2940 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 3437 | 0.020 |
Why?
|
| Testis | 1 | 1989 | 753 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 1834 | 0.020 |
Why?
|
| Esophagoscopy | 1 | 2007 | 309 | 0.020 |
Why?
|
| MutS Homolog 3 Protein | 1 | 2004 | 12 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 874 | 0.020 |
Why?
|
| Ca(2+) Mg(2+)-ATPase | 1 | 1984 | 16 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2005 | 83 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 596 | 0.020 |
Why?
|
| Molecular Biology | 1 | 2006 | 183 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 3033 | 0.020 |
Why?
|
| Basophils | 1 | 2004 | 45 | 0.020 |
Why?
|
| Alanine Transaminase | 2 | 2001 | 240 | 0.020 |
Why?
|
| Keratin-20 | 1 | 2004 | 45 | 0.010 |
Why?
|
| Proteomics | 1 | 2012 | 1435 | 0.010 |
Why?
|
| Tissue Array Analysis | 1 | 2006 | 759 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2006 | 685 | 0.010 |
Why?
|
| Kinetics | 2 | 1978 | 2246 | 0.010 |
Why?
|
| Diploidy | 1 | 2004 | 116 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2010 | 2346 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1989 | 726 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 3073 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2004 | 182 | 0.010 |
Why?
|
| Membrane Glycoproteins | 2 | 2001 | 1107 | 0.010 |
Why?
|
| Mice | 3 | 2016 | 35990 | 0.010 |
Why?
|
| Transfection | 1 | 2009 | 3169 | 0.010 |
Why?
|
| Mercury | 1 | 1983 | 32 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2007 | 1080 | 0.010 |
Why?
|
| Keratins | 1 | 2004 | 352 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2003 | 219 | 0.010 |
Why?
|
| Camptothecin | 1 | 2006 | 538 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 1460 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 1438 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 1152 | 0.010 |
Why?
|
| Pyridines | 1 | 2010 | 1311 | 0.010 |
Why?
|
| Cell Survival | 1 | 2009 | 3081 | 0.010 |
Why?
|
| Incidence | 1 | 2012 | 5840 | 0.010 |
Why?
|
| RNA Interference | 1 | 2006 | 1398 | 0.010 |
Why?
|
| Taxoids | 1 | 2006 | 1008 | 0.010 |
Why?
|
| Esophagectomy | 1 | 2007 | 946 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 7948 | 0.010 |
Why?
|
| L-Iditol 2-Dehydrogenase | 1 | 2001 | 2 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2006 | 1985 | 0.010 |
Why?
|
| Receptors, CXCR3 | 1 | 2001 | 35 | 0.010 |
Why?
|
| Toxicity Tests | 1 | 2001 | 52 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2001 | 262 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2001 | 170 | 0.010 |
Why?
|
| Interphase | 1 | 2000 | 156 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2001 | 210 | 0.010 |
Why?
|
| Longevity | 1 | 2001 | 155 | 0.010 |
Why?
|
| Ki-1 Antigen | 1 | 2001 | 185 | 0.010 |
Why?
|
| Genetic Carrier Screening | 1 | 2000 | 96 | 0.010 |
Why?
|
| Acetylation | 1 | 2001 | 519 | 0.010 |
Why?
|
| Salicylates | 1 | 1999 | 73 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 4385 | 0.010 |
Why?
|
| Gastroscopy | 1 | 1999 | 155 | 0.010 |
Why?
|
| Bismuth | 1 | 1999 | 97 | 0.010 |
Why?
|
| Omeprazole | 1 | 1999 | 111 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 1666 | 0.010 |
Why?
|
| Anti-Ulcer Agents | 1 | 1999 | 127 | 0.010 |
Why?
|
| Fungal Proteins | 1 | 2000 | 271 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 3972 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2000 | 342 | 0.010 |
Why?
|
| United States | 1 | 2016 | 15981 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 540 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 3245 | 0.010 |
Why?
|
| Magnesium | 1 | 1978 | 173 | 0.010 |
Why?
|
| Organometallic Compounds | 1 | 1999 | 209 | 0.010 |
Why?
|
| Kidney | 2 | 1986 | 2260 | 0.010 |
Why?
|
| Tetramethylphenylenediamine | 1 | 1977 | 3 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2006 | 3920 | 0.010 |
Why?
|
| Heterozygote | 1 | 2001 | 1031 | 0.010 |
Why?
|
| Weight Gain | 1 | 2001 | 475 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 1977 | 135 | 0.010 |
Why?
|
| Age of Onset | 1 | 2000 | 824 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2000 | 505 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2000 | 1089 | 0.010 |
Why?
|
| Homozygote | 1 | 2000 | 759 | 0.010 |
Why?
|
| Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone | 1 | 1976 | 8 | 0.010 |
Why?
|
| Membranes | 1 | 1976 | 33 | 0.010 |
Why?
|
| Calcimycin | 1 | 1976 | 53 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2001 | 1619 | 0.010 |
Why?
|
| Egtazic Acid | 1 | 1976 | 60 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2000 | 1567 | 0.010 |
Why?
|
| Androgens | 1 | 2000 | 558 | 0.010 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Light Chain | 1 | 1996 | 5 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2001 | 2250 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1996 | 335 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 2716 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 2 | 1986 | 100 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2000 | 1742 | 0.010 |
Why?
|
| Body Weight | 2 | 1989 | 1333 | 0.010 |
Why?
|
| Drinking | 1 | 1989 | 54 | 0.010 |
Why?
|
| Enzymes | 1 | 1989 | 72 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1993 | 1433 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1989 | 123 | 0.010 |
Why?
|
| Succinate Dehydrogenase | 1 | 1986 | 49 | 0.000 |
Why?
|
| Blood Chemical Analysis | 1 | 1986 | 115 | 0.000 |
Why?
|
| Mercuric Chloride | 1 | 1983 | 4 | 0.000 |
Why?
|
| Kidney Cortex | 1 | 1983 | 37 | 0.000 |
Why?
|
| Renal Circulation | 1 | 1983 | 65 | 0.000 |
Why?
|
| Urine | 1 | 1983 | 142 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 2000 | 5990 | 0.000 |
Why?
|
| Organ Specificity | 1 | 1983 | 751 | 0.000 |
Why?
|
| Glomerular Filtration Rate | 1 | 1983 | 600 | 0.000 |
Why?
|